Skip to content
Synopulse
  • The Brief
    • Quick
    • In Depth
    • Editor’s Pick
  • Reports
    • The beats
      • Catalyst
      • AccessWatch
      • DealPulse Signal
      • DealPulse Report
    • Analysis
      • The Throughline
      • The Top Line
      • The Forecast
    • Coverage
      • ShowFloor
      • The Arena
  • The Pulse
    • NeuroPulse
    • OrphanPulse
  • Topics
    • By subject
      • Deals
      • Regulatory
      • Market Access
      • Pricing & Reimbursement
      • Legal & Policy
    • By technology
      • Antibody
      • Cell & Gene Tx
      • Drug conjugates
      • AI/ML
      • Digital Health
      • Radiopharma
    • By therapy area
      • Neurology
      • Oncology
      • Rare Diseases
      • Cardio-Metabolic
      • Immunology & Inflammation
      • Orthopaedics

Alphamab Oncology

Pathos Put 6% Down on a Phase III ADC, and Alphamab Kept the Market It Can Actually Reach

August 5, 2026 by Athithi Verma
Pathos Put 6% Down on a Phase III ADC, and Alphamab Kept the Market It Can Actually Reach

Fresenius describes an end to end biopharma business. Dr. Reddy’s developed, made and filed this rituximab. Fresenius is only the channel.

Categories Deal Read, Deals, Drug conjugates, Oncology, Quick, The Brief Tags Alphamab Oncology, Bispecific ADC, China, HER3, JSKN016, Pathos AI, TNBC, TROP2, United States
Synopulse Weekly Pulse: Access Decisions, Regulatory Events & Market Dynamics, Week of Nov 24 2025

Synopulse Weekly Pulse – November 24, 2025

Read Now
  • Access Read
  • AI/ML
  • Analysis
  • Antibody
  • Approval
  • Cardio-Metabolic
  • Cell & Gene Tx
  • CI read
  • Clinical Read
  • Coverage
  • Deal Read
  • DealPulse
  • DealPulse Report
  • DealPulse Signal
  • Deals
  • Diagnostics
  • Digital Health
  • Drug conjugates
  • Editor's Pick
  • Immunology & Inflammation
  • In Depth
  • Launch
  • Legal & Policy
  • Market Access
  • MedTech
  • Neurology
  • NeuroPulse
  • News
  • Oncology
  • Ophthalmology
  • OrphanPulse
  • Orthopaedics
  • Peptide
  • Pricing & Reimbursement
  • Pulmonology
  • Quick
  • Radiopharma
  • Rare Diseases
  • Regulatory
  • Reports
  • RNA
  • ShowFloor
  • Small Molecule
  • The beats
  • The Brief
  • The Pulse
  • The Throughline
  • August 2026
  • July 2026
  • June 2026
  • May 2026
  • March 2026
  • January 2026
  • December 2025
  • November 2025
  • October 2025
  • September 2025
  • July 2025
  • June 2025
  • February 2025
  • January 2025
  • October 2024
  • September 2024
Synopulse
Contact Us

Explore Synopulse

  • NeuroPulse
  • Deals
  • Market Access
  • Industry Trends
  • Regulatory

About

  • About Synopulse
  • Contact Us
  • Announcements
© 2026 Synopulse • Built with GeneratePress